Skip to content

Evaluation the effect and safety of terazosin in reducing vascular stiffness: a randomized, double-blind, parallel-controlled clinical trial

Evaluation the effect and safety of terazosin in reducing vascular stiffness: a randomized, double-blind, parallel-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076294
Enrollment
Unknown
Registered
2023-09-28
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular stiffness

Interventions

experimental group:0.5mg terazosin
control group:placebo

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male aged between 40 and 70 years; 2. PWV increased abnormally, exceeding the normal reference value (1400m/s) or considered as stiffness; 3. Without hard cardiovascular disease, including coronary heart disease,acute myocardial infarction, large artery hemangioma and stroke; 4. Normal hepatic and renal functions; 5. Without hematological disorders; 6. Meet the following criteria: a. self-care or basic self-care; b. good nutritional status; c. cognitive function is basically normal; d. optimistic and positive, self-satisfied; e. have certain health literacy and maintain a good lifestyle; f. active participation in family and social activities; g. good social adaptability; 7.Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have taken terazosin or tamsulosin or other a - adrenergic receptor blockers in the past three months; 2. Need to take type 5 phosphodiesterase inhibitors for erectile dysfunction or other diseases; 3. Need to take hypotensive drugs, hypoglycemic drugs or lipid lowering drugs due to abnormal blood pressure, blood glucose or blood lipid; 4. Individuals with angina pectoris, myocardial disease, valvular disease and coronary artery disease; 5. Patients with malignant tumor; 6. Unable to cooperate with treatment and follow-up; 7. Taking drugs that affect coagulation function and platelet function; 8. Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
brachial ankle pulse wave velocity;

Secondary

MeasureTime frame
Cardiovascular events;Blood pressure;related gene sequencing results;flow mediated dilation;Cyclic molecular markers;Carotid intimal medial thickness, IMT;

Countries

China

Contacts

Public ContactCuntai Zhang

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

ctzhang0425@163.com+86 159 2766 8408

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026